Myelotoxicity of oral topotecan in relation to treatment duration and dosage: A phase i study

Anti-Cancer Drugs

Volumn 21, Issue 2, 2010, Pages 202-205

  Stathopoulos, George P ^a   Ardavanis, Alexandros ^b   Papakotoulas, Pavlos ^g   Pectasides, Dimitrios ^c   Papadopoulos, George ^a   Antoniou, Dimosthenis ^d   Athanasiadis, Athanasios ^f   Trafalis, Dimitrios ^a   Anagnostopoulos, Athanasios ^a   Koutantos, John ^a   Vaslamatzis, Michael ^e  

^a Errikos Dunant Hospital   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d Hospital of Thoracic Diseases   (Greece)

^e EVANGELISMOS HOSPITAL   (Greece)

^f GENERAL HOSPITAL   (Greece)

^g THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Myelotoxicity; Oral; Topotecan

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HYCAMPTIN; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 76149104592     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283350092     Document Type: Article

References (23)

1. Burris HA III, Hanauske AR, Johnson RK, Marschal MH, Kuhn JG, Hilsenbeck SC, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84:1816-1820.
2. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10 hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992; 31:229-233.
3. Kingsbury WD, Boehm JC, Jakas DR, Halden KG, Hecht SM. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991; 34:98-107.
4. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15:2090-2096.
5. Markman M. Topotecan: an important new drug in the management of ovarian cancer. Semin Oncol 1997; 4 (Suppl 5):55-58.
6. Bokkel Huinick WT, Gore M, Carmichael J, Gorden A, Malfetano J, Hudson I, et al. Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183-2193. (Pubitemid 27251118)
7. Belinson J, Kennedy A, Webster K, Kulp B, Peterson G, Markman M. Preliminary results of a Cleveland Clinic Cancer Center Gynecologic Oncology Program phase 2 trial of topotecan administered on a 3-day schedule as salvage therapy of platinum and paclitaxel refractory ovarian cancer. [abstract] Proc Am Soc Clin Oncol 1999; 18:369a.
8. Sun W, Stevenson JP, Gallagher M, Giantonio B, Algazy K, Haller D, et al. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 2001; 92:414-419.
9. Rowinsky EK.Weekly topotecan: an alternative to topotecan's standard daily X 5 day schedule? Oncologist 2002; 7:324-328.
10. Stathopoulos GP, Rigatos SK, Christodoulou Ch, Malamos NA, Deliyiannis F, Stathopoulos JG, et al. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 2004; 54:259-264.
11. Stathopoulos GP, Katis C, Tsavdaridis D, Dimitroulis J, Karaindros D, Stathopoulos J, et al. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial. Cancer Chemother Pharmacol 2006; 58:555-560.
12. Von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, et al. A phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small cell lung cancer. J Clin Oncol 2001; 19:1743-1749.
13. Eckardt JR, Von Pawel J, Hainsworth JD, Corso S, Rimaldi D, Preston A, et al. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC): an international phase III study. [abstract 2488]. Proc Am Soc Clin Oncol 2003; 22:619.
14. Gerrits CJH, Burris H, Schellens JMH, Eckardt JR, Planting AST, van der Berg MEL, et al. 5 days of once daily oral topotecan a phase I and pharmacologic study in adults. Ann Oncol 1996; 7 (Suppl 5):5970.
15. National Cancer Institute, Cancer therapy evaluation programs Common Toxicity Criteria Version 2.0, 1999.
16. Gerrits CJH, Schellens JHM, Burris H, Eckhardt JR, Planting AST, van der Berg MEL, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamptin). Clin Cancer Res 1999; 5:69-75.
17. O'Reilly S. Topotecan: what dose, what schedule, what route? Clin Cancer Res 1999; 5:3-5.
18. Gralla RJ, Eckardt J, Grotzinger KM. Quality of life with single agent oral topotecan vs intravenous topotecan in patients with chemosensitive small cell lung cancer [SCLC (Suppl 2; abstract P-578)]. Lung Cancer 2003; 41:S237.
19. Nicum SJ, O'Brien MER. Topotecan for the treatment of small-cell lung cancer. Expert Rev Anticancer Ther 2007; 7:795-801.
20. O'Reilly S, Armstrong DK, Grochow LB. Life threatening myelosuppression in patients with occult renal failure receiving topotecan. Gynecol Oncol 1997; 15:329-330.
21. Armstrong DK, O'Reilly S. Clinical guidelines for managing topotecan related hematologic toxicity. Oncologist 1998; 3:4-10.
22. Miller AA, Libenbaum RC, Lynch TJ, Rosner GL, Ratain MJ, Green MR, et al. Treatment related fatal sepsis from topotecan/cisplatin and topotecan/ paclitaxel. J Clin Oncol 1996; 14:1964-1965.
23. Libenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, et al. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol 1995; 13:2230-2237.